LDN-212854 is an potent, ALK2-biased BMP type I receptor kinase (ACVR1) inhibitor that potently inhibits ALK2 (IC50=1.3 nM) and ALK1 (IC50=2.40 nM). LDN-212854 potently inhibits heterotopic ossification in an inducible transgenic mutant ALK2 mouse model of fibrodysplasia ossificans progressiva. LDN-212854 suppresses HCC tumor progression through repression of ID1 in HCC xenografts model.
